Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia

Opus · July 18, 2018, 9:38pm

This might be worth signing up too if your in one of the areas of the study.

far_cry0 · July 19, 2018, 4:22am

I think its for cognitive symptoms…right @Opus…??

Opus · July 19, 2018, 6:36am

Yeah thats what it says

Topic		Replies	Views
Upcoming medications DX'd - Other	7	371	September 1, 2021
Boehringer Ingelheim's Investigational Treatment for Cognitive Impairment Associated with Schizophrenia Receives FDA Breakthrough Therapy Designation News	3	386	May 24, 2021
Phase 3 trial of BI 425809 Medications	1	227	December 12, 2020
Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial News	2	461	May 3, 2018
BI 409306 studied in cognition in sz phase 2, but how did it do? News	5	1188	March 23, 2017